Measurement of Platelet Dense Granule Release in Healthy Volunteers
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- The primary measurement will be platelet 5-HT release induced by ADP after 1 and 2 weeks administration of daily ASA.
研究概览
简要总结
Aspirin has been shown to reduce cardiovascular events in at risk individuals. Elucidation of mechanisms of aspirin resistance and a possible loss of effect of aspirin over time with chronic aspirin treatment necessitate a more precise method of measuring the "release phase" of platelet activation, including the release of dense granules from platelets.
详细描述
This is a proposal for a pilot study to evaluate the feasibility of measuring 5-hydroxytryptamine (5-HT) release from platelets as an indicator of dense granule release during platelet activation in volunteers taking aspirin.
One phase of platelet response to activating agonists involves release of dense granules, which are known to contain 5HT (serotonin) and ATP. There are various methods of measuring the degranulation of platelets: ATP release can be measured using a lumiaggregometer, and release of 14C radiolabeled 5-HT from platelets. Using the aggregometer and a 14C labeled 5-HT assay can be used to measure 5-HT release from platelets.
Our experience suggests that ADP-induced ATP release is insensitive to detect very low levels of platelet dense granule release, which occurs in aspirin-treated subjects. The pilot study will permit optimizing the method for reliably detecting low levels of 5HT release in patients who achieve submaximal inhibition of the cyclooxygenase during aspirin treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Males over age 18
- •Non-smokers
- •No chronic medical illness
- •No chronic medications
排除标准
- •ASA/NSAID use previous 14 days.
- •History of chronic NSAID use.
- •Currently taking NSAIDs, opioid analgesics, corticosteroids, or anticoagulants.
- •History of coronary artery disease, myocardial infarction, coronary artery bypass grafting, percutaneous angioplasty, diabetes mellitus or stroke.
- •History of hypertension
- •History of gastric, duodenal, or esophageal ulcers or serious gastrointestinal bleed.
- •History of frequent headaches, pain syndrome, or other condition requiring frequent use of analgesics.
- •History of adverse reaction to ASA.
- •Initial platelet count <100K/µl or >500K/µl.
- •Initial hematocrit <35% or >50%.
- •Weight less than 110 pounds.
- •Female subjects will be excluded to avoid possible confounding uterine smooth muscle production of prostaglandins which various throughout the menstrual cycle.
研究组 & 干预措施
40 mg non-enteric coated aspirin
40 mg non-enteric coated ASA once daily for 21 + or - 2 days
干预措施: Aspirin (Drug)
结局指标
主要结局
The primary measurement will be platelet 5-HT release induced by ADP after 1 and 2 weeks administration of daily ASA.
时间窗: 3 weeks
次要结局
- Measurements will include platelet COX-1 activity, flow cytometric measurement of markers of platelet activation, platelet aggregation and ATP release, and serum thromboxane B2 (TxB2) levels, at each timepoint.(3 weeks)
研究者
John Oates
Professor of Medicine and Pharmacology
Vanderbilt University